Key result
Three metabolic risk factors linked to ~8-fold higher cardiovascular risk in MASLD.
Why the study?
Does a higher metabolic risk factor burden increase 10-year ASCVD risk in patients with MASLD?
Cross-Sectional (n=357)
Does a higher metabolic risk factor burden increase 10-year ASCVD risk in patients with MASLD?
In patients with MASLD, a higher burden of metabolic risk factors is strongly associated with an increased 10-year estimated ASCVD risk, highlighting the need for targeted cardiovascular prevention.
BACKGROUND: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a spectrum of hepatic disorders that are closely linked to metabolic risk factors. This study aimed to investigate the stratified cardiovascular risk in patients with MASLD based on varying metabolic risk burdens. METHODS: In a cross-sectional analysis, 357 patients with MASLD were classified into three subtypes based on the number of metabolic conditions used for diagnosis: subtype 1 with one metabolic risk factor (n = 110), subtype 2 with two (n = 161), and subtype 3 with three risk factors (n = 86). Clinical parameters, liver enzymes, lipid profiles, and 10-year risk of Atherosclerotic Cardiovascular Disease (ASCVD) were compared among subtypes. RESULTS: The prevalence of diabetes and hypertension increased significantly across subtypes, with subtype 3 showing the highest burden of cardiovascular risk factors (100% diabetes, 43% hypertension). Cardiovascular risk was elevated in subtype 3 (mean ASCVD 0.112 ± 0.108, p < 0.001). Multivariate analysis identified subtype 3 (OR = 7.812, 95% CI 1.980-30.819, p = 0.003), men sex (OR = 33.549, 95% CI 11.814-95.269, p < 0.001), and age (OR = 1.171, 95% CI 1.116-1.229, p < 0.001) as independent predictors of intermediate to high cardiovascular risk. CONCLUSION: The metabolic burden in patients with MASLD significantly stratified cardiovascular risk. Patients with the highest metabolic dysfunction are at increased risk of cardiovascular events, underscoring the need for targeted cardiovascular prevention strategies.
No takes yet. Share an insight, caveat, or question.
Elsabaawy et al. (2025) conducted a cross-sectional in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (n=357). Three metabolic risk factors (subtype 3) vs. One or two metabolic risk factors (subtypes 1 and 2) was evaluated on Intermediate to high cardiovascular risk (OR 7.812, 95% CI 1.980-30.819, p=0.003). In patients with MASLD, having three metabolic risk factors was an independent predictor of intermediate to high cardiovascular risk (OR 7.812; 95% CI 1.980-30.819; p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: